Skip to main content

Advertisement

Table 3 Uterine cancer characteristics, adjuvant therapy and disease status

From: Safety and feasibility of contained uterine morcellation in women undergoing laparoscopic hysterectomy

Characteristic Uterine cancer (N = 53)
Pre-op Histology (n = 49)
 Endometrioid 34 (69.4)
 Serous 6 (12.2)
 Clear cell 3 (6.1)
 Carcinosarcoma 3 (6.1)
 Other/unspecified 7 (14.3)
Post-op Histology
 Endometrioid 40 (75.5)
 Serous 5 (9.4)
 Clear cell 1 (1.9)
 Carcinosarcoma 7 (13.2)
Grade
 1 21 (39.6)
 2 15 (28.3)
 3 17 (32.1)
Stage
 IA 28 (52.8)
 IBa 15 (28.3)
 II 1 (1.9)
 IIIA 2 (3.8)
 IIIC1 3 (5.7)
 IIIC2 2 (3.8)
 IVB 2 (3.8)
Lymph nodes
 Positive 6 (11.32)
 Negative 29 (54.7)
 Not collected 18 (34.0)
Pelvic Washings
 Positive 5 (9.4)
 Negative 41 (77.4)
 Indeterminate/suspicious 6 (11.3)
 Not collected 1 (1.9)
Adjuvant Therapyb
 Radiation 13 (24.5)
 Chemotherapy 10 (18.9)
 Hormonal 4 (7.6)
Recurrence rate 7 (13.2)
Median time to recurrence (days) 395 [range 128–539]
Status of disease
 No evidence of disease 43 (81.1)
 Alive with diseasec 3 (5.7)
 Died of disease 5 (9.4)
 Died of intercurrent disease 1 (1.9)
 Died of unknown caused 1 (1.9)
  1. Data are n(%) unless otherwise specified
  2. aDepth of invasion could not be determined in one case and is included in the Stage 1B group
  3. bChemotherapy: Carboplatin/Taxol (6), Carboplatin/Taxol + Cisplatin (with radiation) (1), Carboplatin/Taxol + Doxil (1); Ifosfamide/Taxol (2). Radiation: vaginal brachytherapy (5), external beam radiation (4), IMRT (2), vaginal brachytherapy + external beam radiation (1). Hormonal: Megace (2), Megace + Tamoxifen (1), Megace + Anastrozole (1)
  4. c(1) IIIC-2, grade 2 endometrioid, disease-free survival 7.8 months (2) IA, grade 2 endometrioid, disease-free survival 13.2 months (3) IB, grade 3 endometrioid, disease-free survival 4.3 months
  5. dMost likely this patient died of disease given her disease distribution with distant metastases